Showing 6161-6170 of 9147 results for "".
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Can-Fite Receives Notice of Allowance in US for Psoriasis Patenthttps://practicaldermatology.com/news/can-fite-receives-notice-of-allowance-in-us-for-psoriasis-patent/2459005/Can-Fite BioPharma Ltd. received a Notice of Allowance from the US Patent and Trademark Office for CF101 in the treatment of psoriasis. The patent, which is expected to be issued in the next few weeks, is titled, "Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-M
- derma e® Introduces Scalp Relief Hair Carehttps://practicaldermatology.com/news/derma-e-introduces-scalp-relief-hair-care/2459006/derma e® launched its new Scalp Relief Shampoo and Conditioner. derma e® Scalp Relief Shampoo and Scalp Relief Conditioner work in four therapeutic ways to effectively target scalp problems. The shampoo is designed to cleanse, de-flake, soothe and nourish. The conditioner is designed to d
- Syneron Medical Appoints William Griffing to Newly Created Position of CEO of Syneron Candela North Americahttps://practicaldermatology.com/news/syneron-medical-appoints-william-griffing-to-newly-created-position-of-ceo-of-syneron-candela-north-america/2459009/Syneron Medical Ltd. appointed William Griffing to the newly created position of Chief Executive Officer of Syneron Candela North America, effective immediately. In this position, Mr. Griffing will be responsible for aligning and managing the Company's growth strategies for its North American
- New App for Clinical Skin Cancer Diagnosis Launches on World Cancer Day 2015; Physician Input Soughthttps://practicaldermatology.com/news/new-app-for-clinical-skin-cancer-diagnosis-launches-on-world-cancer-day-2015-physician-input-sought/2459012/On World Cancer Day 2015, general practitioners, physicians, and dermatologists in the United States, United Kingdom and Australia were asked for their feedback during the advanced trial phase of a new, free app that has the potential to play a role in the clinical detection of skin cancer.
- Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Officehttps://practicaldermatology.com/news/provectus-biopharmaceuticals-novel-synthesis-patent-application-allowed-by-chinese-patent-office/2459017/Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company (
- FDA Approves First IL-17A antagonist Cosentyx (secukinumab) from Novartis for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-first-il-17a-antagonist-cosentyx-secukinumab-from-novartis-for-moderate-to-severe-plaque-psoriasis/2459019/The FDA approved Cosentyx™ (secukinumab) from Novartis for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosentyx is the first approved psoriasis medication to selectively bind to IL-17A and inhibit its intera
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- BioD Receives US Patent for Placental Tissue Technology for Improved Wound Care and Healinghttps://practicaldermatology.com/news/biod-receives-us-patent-for-placental-tissue-technology-for-improved-wound-care-and-healing/2459024/BioD, LLC received its first patent for one of its platform tissue technologies. On January 13, 2015, the US Patent and Trademark Office issued US Patent Number 8,932,805, “Birth Tissue Material and Method of Preparation.” The patent covers the company’s BioDFactor® Viable T
- Celsus Therapeutics Receives FDA Allowance of IND in Atopic Dermatitishttps://practicaldermatology.com/news/celsus-therapeutics-receives-fda-allowance-of-ind-in-atopic-dermatitis/2459026/Celsus Therapeutics will expand its clinical program in atopic dermatitis in the US, now that the FDA has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The Com